Recruitment

Recruitment Status
Unknown status

Inclusion Criterias

NSCLC proved by a histological biopsy
age over superior to 18
patients who have signed an informed consent to participate in this study
...
NSCLC proved by a histological biopsy
age over superior to 18
patients who have signed an informed consent to participate in this study
EGFR mutation status known with no activating EGFR mutation
life expectancy exceeding 12 weeks
WHO activity score between 0 and 2.
indication of erlotinib therapy after at least one previous therapy

Exclusion Criterias

contraindication for the initiation of erlotinib
life expectancy less than 12 weeks
refusal to sign the consent
...
contraindication for the initiation of erlotinib
life expectancy less than 12 weeks
refusal to sign the consent
infection with the HIV virus
major adults protected by French law
progressive inflammatory disease
other malignant disease

Summary

Conditions
  • No EGFR Activating Mutation
  • Non-small Cell Lung Cancer Metastatic or Non-small Cell Lung Cancer Recurrent
Type
Interventional
Phase
Phase 2
Design
  • Allocation: N/A
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label)

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Inclusion Criterias

NSCLC proved by a histological biopsy
age over superior to 18
patients who have signed an informed consent to participate in this study
...
NSCLC proved by a histological biopsy
age over superior to 18
patients who have signed an informed consent to participate in this study
EGFR mutation status known with no activating EGFR mutation
life expectancy exceeding 12 weeks
WHO activity score between 0 and 2.
indication of erlotinib therapy after at least one previous therapy

Exclusion Criterias

contraindication for the initiation of erlotinib
life expectancy less than 12 weeks
refusal to sign the consent
...
contraindication for the initiation of erlotinib
life expectancy less than 12 weeks
refusal to sign the consent
infection with the HIV virus
major adults protected by French law
progressive inflammatory disease
other malignant disease

Locations

Rouen, Seine maritime, 76000
Toulouse, Haute Garonne, 31000
Tours, Indre et Loire, 37000
Percy, Haut de Seine, 92140
Bordeaux, Gironde, 33000
...
Rouen, Seine maritime, 76000
Toulouse, Haute Garonne, 31000
Tours, Indre et Loire, 37000
Percy, Haut de Seine, 92140
Bordeaux, Gironde, 33000
Nancy, Meurthe et Moselle, 54000
Créteil, Val de Marne, 94000
Angers, Maine et Loire, 49933

Tracking Information

NCT #
NCT02069418
Collaborators
  • University Hospital, Tours
  • Army Hospital, Percy
  • Créteil Hospital
  • University Hospital, Rouen
  • Central Hospital, Nancy, France
  • University Hospital, Toulouse
  • University Hospital, Bordeaux
Investigators
  • Principal Investigator: José HUREAUX, MD, PhD University Hospital, Angers Study Chair: Olivier COUTURIER, MD, PhD University Hospital, Angers
  • José HUREAUX, MD, PhD University Hospital, Angers Study Chair: Olivier COUTURIER, MD, PhD University Hospital, Angers